Aging Clinical Trial
Official title:
Optimization of Transcranial Direct Current Stimulation (tDCS) for Dual Task Performance in Older Adults With and Without a History of Falls
| NCT number | NCT03191812 |
| Other study ID # | 2016-26 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | |
| Last updated | |
| Start date | May 26, 2017 |
| Est. completion date | May 26, 2021 |
| Verified date | March 2022 |
| Source | Hebrew SeniorLife |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The tDCS & Dual Tasking study will compare the effects of transcranial Direct Current Stimulation (tDCS) targeting three different cortical regions (as well as sham stimulation) on dual task standing and walking in older adults with and without a recent history of recurrent falls.
| Status | Completed |
| Enrollment | 61 |
| Est. completion date | May 26, 2021 |
| Est. primary completion date | November 26, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 65 Years and older |
| Eligibility | Inclusion Criteria: "Faller" group - Aged 65 years and older - Able to read, write and communicate in English - Self-report of 2 or more falls within the past 6 months "Non-Faller" Group - Aged 65 years and older - Able to read, write, and communicate in English - Self-report of 1 or no (zero) falls within the past 6 months Exclusion Criteria: - Self-reported diagnosis of Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, history of stroke or other neurodegenerative disorder. - Self-reported active cancer for which chemo-/radiation therapy is being received. - Hospitalization within the past 3 months due to acute illness or as a result of a musculoskeletal injury significantly affecting gait and balance. - Montreal Cognitive Assessment score <18, or insufficient understanding of study procedures following review of the Informed Consent Form. Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator. - Inability to stand or ambulate unassisted for at least 25 feet. - Contraindications to tDCS, including a reported seizure within the past two years, use of neuro-active drugs, the risk of metal objects in the brain, skull, or head, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant), or the presence of any active dermatological condition, such as eczema, on the scalp (see appendix for standardized tDCS screening questionnaire). |
| Country | Name | City | State |
|---|---|---|---|
| Israel | Laboratory for Gait and Neurodynamics, Tel Aviv Sourasky Medical Center | Tel Aviv | |
| United States | Hebrew Rehabilitation Center | Roslindale | Massachusetts |
| Lead Sponsor | Collaborator |
|---|---|
| Hebrew SeniorLife |
United States, Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Dual task cost to standing postural sway speed | The dual task cost to standing postural sway speed will be calculated from trials of standing with and without simultaneous performance of a serial subtraction cognitive task. The dual task cost will be calculated as the percent change in sway speed from single- to dual-task conditions. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Primary | Dual task cost to gait speed when walking | The dual task cost to gait speed when walking will be calculated from trials of walking with and without simultaneous performance of a serial subtraction cognitive task. The dual task cost will be calculated as the percent change in gait speed from single- to dual-task conditions. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Dual task cost to postural sway area | The dual task cost to standing postural sway area will be calculated from trials of standing with and without simultaneous performance of a serial subtraction cognitive task. The dual task cost will be calculated as the percent change in postural sway area from single- to dual-task conditions. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Dual task cost to gait variability when walking | The dual task cost to gait variability when walking will be calculated from trials of walking with and without simultaneous performance of a serial subtraction cognitive task. Gait variability will be defined as the coefficient of variation about the average stride time (stride times defined by the time between consecutive heel strides of the same leg). The dual task cost will be calculated as the percent change in gait variability from single- to dual-task conditions. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Single task postural sway speed | Single task postural sway speed will be calculated from trials of standing without simultaneous performance of a serial subtraction cognitive task. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Single task postural sway area | Single task postural sway area will be calculated from trials of standing without simultaneous performance of a serial subtraction cognitive task. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Single task gait speed variability when walking | Single task gait variability when walking will be calculated from trials of walking without simultaneous performance of a serial subtraction cognitive task. Gait variability will be defined as the coefficient of variation about the average stride time (stride times defined by the time between consecutive heel strides of the same leg). | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Single task gait speed when walking | Single task gait speed when walking will be calculated from trials of walking without simultaneous performance of a serial subtraction cognitive task. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Mobility | Mobility will be assessed using the Timed Up-and-Go test in which the amount of time it takes for the participant to stand up from a chair, walk three meters, turn around a cone, walk back, and sit down is recorded. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Executive function | Executive function will be assessed using the Stroop test. | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Cognitive processing speed | Cognitive processing speed will be assessed using the Symbol Digit Modalities Test (SDMT). | This outcome will be assessed immediately before and after each 20-minute session of tDCS. | |
| Secondary | Attention | Attention will be assessed using the Visual Search and Attention Test (VSAT). | This outcome will be assessed immediately before and after each 20-minute session of tDCS |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
| Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
| Completed |
NCT05293730 -
Trial of the Impact of the Electronic Frailty Integrated With Social Needs
|
N/A | |
| Recruiting |
NCT03932162 -
Gene Expression Changes In Young and Geriatric Skin
|
Early Phase 1 | |
| Completed |
NCT04064528 -
Effects of Age on Amino Acid Delivery to Tendon
|
N/A | |
| Completed |
NCT03366129 -
Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
|
||
| Completed |
NCT06029920 -
Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment
|
N/A | |
| Recruiting |
NCT05543980 -
Leg Heat Therapy in Elderly Individuals
|
Phase 2 | |
| Recruiting |
NCT05566938 -
Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly
|
N/A | |
| Completed |
NCT04894929 -
Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement
|
N/A | |
| Not yet recruiting |
NCT06071130 -
Emotion, Aging, and Decision Making
|
N/A | |
| Enrolling by invitation |
NCT04641663 -
Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST)
|
N/A | |
| Completed |
NCT04088006 -
The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity
|
N/A | |
| Completed |
NCT03695081 -
Patient Pathway Pharmacist - Optimal Drug-related Care
|
N/A | |
| Recruiting |
NCT05424263 -
Acetate and Age-associated Arterial Dysfunction
|
Phase 2 | |
| Completed |
NCT05601713 -
Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling
|
N/A | |
| Completed |
NCT04551339 -
Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19
|
N/A | |
| Recruiting |
NCT04997577 -
Speech Perception and High Cognitive Demand
|
N/A | |
| Completed |
NCT05922475 -
Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training
|
N/A | |
| Completed |
NCT04015479 -
Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults
|
N/A |